ADARx Pharmaceuticals

ADARx Pharmaceuticals to Present at the J.P. Morgan 42nd Annual Healthcare Conference

The ADARx Team

SAN DIEGO, Calif. – January 3, 2024 – ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PT in San Francisco, California.  

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA. ADARx has a growing pipeline of RNA therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiovascular, complement-mediated and central nervous system diseases. Follow ADARx on LinkedIn.

Contact ADARx Pharmaceuticals

Roselle Corbaley

(877) 232-7974
ir@adarx.com

Scroll to Top